# Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation

> **NCT07499271** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 35 (estimated)

## Conditions studied

- Diffuse Large B-Cell Lymphoma (DLBCL)

## Interventions

- **DRUG:** POLA-R-CHP
- **DRUG:** Orelabrutinib

## Key facts

- **NCT ID:** NCT07499271
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07499271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07499271, "Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07499271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*